Direct Detection of miR-122 in Hepatotoxicity Using Dynamic Chemical Labeling Overcomes Stability and isomiR Challenges

López‐Longarela, Bárbara; Morrison, Emma; Tranter, John D.; Chahman-Vos, Lianne; Léonard, Jean-François; Gautier, Jean‐Charles; Laurent, Sébastien; Lartigau, Aude; Boitier, Eric; Sautier, Lucile; Carmona-Sáez, Pedro; Martorell-Marugán, Jordi; Mellanby, Richard J.; Pernagallo, Salvatore; Ilyine, Hugh; Rissin, David M.; Duffy, David C.; Dear, James W.; Díaz‐Mochón, Juan José

doi:10.1021/acs.analchem.9b05449

Cited by 44 publications

(49 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study, we have demonstrated that for miR-126 this is not the case: significant degradation occurred if the sample was left unprocessed for 24hr. We have reported similar instability for miR-122 (Lopez-Longarela et al, 2020). We also demonstrated that hemolysis may increase the concentration of miR-126 present in the sample.…”

Section: Ll Open Accesssupporting

confidence: 74%

Circulating argonaute-bound microRNA-126 reports vascular dysfunction and treatment response in acute and chronic kidney disease

et al. 2021

Self Cite

View full text Add to dashboard Cite

Summary Vascular and kidney dysfunction commonly co-exist. There is a need for biomarkers of vascular health. Circulating microRNAs are biomarkers; miR-126 is endothelial cell-enriched. We measured circulating miR-126 in rats with nephrotoxic nephritis (NTN) and humans with acute endothelial and renal injury (vasculitis associated with autoantibodies to neutrophil cytoplasm antigens (ANCAs)). We compared these findings to those from patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) and explored the relationship between miR-126 and vascular dysfunction. In NTN, miR-126 was reduced. In ANCA vasculitis (N = 70), pre-treatment miR-126 was reduced compared to health (N = 60) (88-fold). miR-126 increased 3.4-fold post-treatment but remained lower than in health (∼26-fold). Argonaute 2-bound miR-126 increased with ANCA vasculitis treatment. miR-126 did not differ between CKD (N = 30) and health but its concentration correlated with endothelial dysfunction. miR-126 was reduced in ESRD (N = 15) (∼350 fold). miR-126 may be a marker of vascular inflammation and could aid decision-making.

show abstract

Section: Ll Open Accesssupporting

confidence: 74%

Circulating argonaute-bound microRNA-126 reports vascular dysfunction and treatment response in acute and chronic kidney disease

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…We have reported similar instability for miR-122. 41 We also demonstrated that hemolysis may increase the concentration of miR-126 present in the sample. Furthermore, despite reports that miRs are detected at similar concentrations in plasma and serum, plasma miR-126 was substantially higher than serum.…”

Section: Discussionmentioning

confidence: 59%

Circulating argonaute-bound microRNA-126 reports vascular dysfunction & response to treatment in acute & chronic kidney disease

Scullion

Vliegenthart

Rivoli

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Vascular and kidney dysfunction commonly co-exist. There is an unmet need for biomarkers of vascular health. Circulating microRNAs (miRs) are disease biomarkers; miR-126 is endothelial cell-enriched. We measured circulating miR-126 in rats with nephrotoxic nephritis (NTN) and humans with acute endothelial and renal injury (vasculitis associated with autoantibodies to neutrophil cytoplasm antigens (ANCA)). We then compared these findings to those from patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD), and explored the relationship between miR-126 and markers of vascular dysfunction. Methods: In rats, NTN was induced with nephrotoxic serum. Samples were prospectively collected from 70 patients with ANCA vasculitis (at presentation and once in treatment-induced remission), healthy subjects (n=60), patients with CKD (n=30) and ESRD before and after dialysis (n=15). In humans and rats, miR-126 and miR-122 (liver-specific control) were measured and correlated with vascular function. Results: In NTN rats, miR-126 was selectively reduced. In ANCA vasculitis, pre-treatment circulating miR-126 was reduced compared to health (88-fold reduction, ROC-AUC 0.87 (0.80-0.94)). miR-126 increased 3.4-fold post-treatment but remained lower than in health (~26-fold). There was no change in miR-122. Plasma fractionation demonstrated that argonaute 2-bound miR-126 increased with treatment of ANCA vasculitis. Urinary miR-126 decreased post-treatment. miR-126 did not differ between CKD and health but its concentration significantly correlated with measures of endothelial dysfunction. miR-126 was substantially reduced in ESRD (~350 fold compared to health and CKD). Conclusions: miR-126 may be a marker of vascular inflammation and has the potential to aid in clinical decision-making.

show abstract

“…The detection may be done with any methodology (chemiluminescent, fluorescent, or colorimetric), depending on the type of modification the SMART-NB carries. The technology may be used for direct detection from several sources, including biofluids, avoiding RNA extraction, RT and/or PCR amplification and it has been validated in several contexts for miRNAs analysis [155][156][157][158][159].…”

Section: Chem-natmentioning

confidence: 99%

Measurements Methods for the Development of MicroRNA-Based Tests for Cancer Diagnosis

Precazzini

Detassis²,

Imperatori

et al. 2021

IJMS

View full text Add to dashboard Cite

Studies investigating microRNAs as potential biomarkers for cancer, immune-related diseases, or cardiac pathogenic diseases, among others, have exponentially increased in the last years. In particular, altered expression of specific miRNAs correlates with the occurrence of several diseases, making these molecules potential molecular tools for non-invasive diagnosis, prognosis, and response to therapy. Nonetheless, microRNAs are not in clinical use yet, due to inconsistencies in the literature regarding the specific miRNAs identified as biomarkers for a specific disease, which in turn can be attributed to several reasons, including lack of assay standardization and reproducibility. Technological limitations in circulating microRNAs measurement have been, to date, the biggest challenge for using these molecules in clinical settings. In this review we will discuss pre-analytical, analytical, and post-analytical challenges to address the potential technical biases and patient-related parameters that can have an influence and should be improved to translate miRNA biomarkers to the clinical stage. Moreover, we will describe the currently available methods for circulating miRNA expression profiling and measurement, underlining their advantages and potential pitfalls.

show abstract

Direct Detection of miR-122 in Hepatotoxicity Using Dynamic Chemical Labeling Overcomes Stability and isomiR Challenges

Cited by 44 publications

References 26 publications

Circulating argonaute-bound microRNA-126 reports vascular dysfunction and treatment response in acute and chronic kidney disease

Circulating argonaute-bound microRNA-126 reports vascular dysfunction and treatment response in acute and chronic kidney disease

Circulating argonaute-bound microRNA-126 reports vascular dysfunction & response to treatment in acute & chronic kidney disease

Measurements Methods for the Development of MicroRNA-Based Tests for Cancer Diagnosis

Contact Info

Product

Resources

About